EN | UA
EN | UA

Help Support

Back

Effect of tanezumab on work productivity, health status, and non-work activities in osteoarthritis

osteoarthritis osteoarthritis
osteoarthritis osteoarthritis

This exploratory pooled analysis of two large phase III osteoarthritis studies aimed to determine tanezumab's effect on health status, work productivity, and non-work activities in osteoarthritis patients.

See All

Key take away

In adults with moderate-to-severe osteoarthritis, subcutaneous tanezumab administration led to

remarkable improvements in work productivity, health status, and non-work activities at week 16.

Background

This exploratory pooled analysis of two large phase III osteoarthritis studies aimed to determine tanezumab's effect on health status, work productivity, and non-work activities in osteoarthritis patients.

Method

In people suffering from osteoarthritis of the knee or hip, subcutaneous tanezumab (5 mg, 2.5 mg) was investigated in placebo-controlled, double-blind, 16-week and 24-week clinical trials. At the baseline and 16th week, all the people finished the EQ-5D-5L (health-related, quality of life questionnaire) and the Work Productivity and Activity Impairment-osteoarthritis (WPAI-OA) activity impairment item.

People who were currently employed also finished the WPAI-OA work time missed, overall work impairment items, and impairment while working. With the aid of analysis of covariance, the between-group differences in the least squares mean alterations from baseline at week 16 were evaluated.

Result

Out of 1545 pooled people, 576 people were employed at the baseline. Compared to placebo, the tanezumab 2.5-mg group exhibited substantial improvements in EQ-5D-5L index value, percent improvements in activity impairment, impairment while working, and overall work disability at the 16th week.

The results for the 5-mg tanezumab group were similar to the 2.5-mg tanezumab group. However, the percent improvement in the work time missed was considerably higher for the 5-mg tanezumab group, but not the 2.5-mg tanezumab group when compared to the placebo group.

Conclusion

Compared with placebo, the monoclonal antibody tanezumab substantially improved the health status, non-work activities, and work productivity in people having osteoarthritis of knee or hip.

Source:

BMC Musculoskeletal Disorders

Article:

Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis

Authors:

Philip G Conaghan et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: